FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306952312> ?p ?o ?g. }

• W4306952312 endingPage "1657" @default.
• W4306952312 startingPage "1657" @default.
• W4306952312 abstract "Venous thromboembolism (VTE) is a major cause of death in the world. After the acute-phase treatment, the optimal duration of anticoagulation is still debatable. The latest guidelines suggest maintaining long-term anticoagulation in patients with cancer-associated thrombosis (CAT) or with unprovoked VTE and a low bleeding risk. Methods: The MAC Project is an ongoing prospective-cohort, multi-center, observational study in Italy. The project aims to collect real-life clinical information in unselected patients given oral anticoagulants for VTE over a 5-year follow-up period. There were no exclusion criteria, except for life expectancy <6 months and refusal to sign the informed consent form or to attend the planned follow-up visit. All patients were followed-up prospectively with clinical controls scheduled at 3, 6, and 12 months after the index event, and then annually for up to 5 years. The primary efficacy and safety outcomes were symptomatic recurrent VTE and major bleeding. Results: We analyzed 450 consecutive patients treated with rivaroxaban and referred them to the MAC Project database for unprovoked or recurrent VTE. Of these, 267 (55%) were unprovoked VTE, and 377 (87%) were symptomatic. We followed up with the patients for a mean of 22 months (Q1 10.7; Q3 37.4 months). Recurrent VTE occurred in 12 patients on rivaroxaban treatment (IR 1.7 per 100 person-years). Males had more recurrence than women. During the follow-up period, we recorded 13 (2.9%) major bleeding, 12 (2.7%) clinically relevant non-major bleeding, 8 minor bleeding, and no fatal bleeding events. Overall, bleeding events occurred in 33 (7.3%) patients, most occurring within the first 2 years of treatment. In addition, we observed a statistically significant higher incidence of bleeding in patients with a baseline HAS-BLED score of 3 to 4 compared with those with a score of 0 to 2, with most events occurring during the first 3 months of treatment (RR 5.9). Discussion: Rivaroxaban appears to be safe and effective for the long-term treatment of patients with recurrent or unprovoked VTE. Our results match previously published data, and we are confident that the continuation of the follow-up for up to 5 years will confirm these outcomes." @default.
• W4306952312 created "2022-10-21" @default.
• W4306952312 creator A5009702302 @default.
• W4306952312 creator A5010777746 @default.
• W4306952312 creator A5020660579 @default.
• W4306952312 creator A5024526302 @default.
• W4306952312 creator A5030714095 @default.
• W4306952312 creator A5031677659 @default.
• W4306952312 creator A5032117981 @default.
• W4306952312 creator A5040457683 @default.
• W4306952312 creator A5055494472 @default.
• W4306952312 creator A5058333665 @default.
• W4306952312 creator A5062127717 @default.
• W4306952312 creator A5068038602 @default.
• W4306952312 creator A5068127125 @default.
• W4306952312 date "2022-10-20" @default.
• W4306952312 modified "2023-09-26" @default.
• W4306952312 title "Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project" @default.
• W4306952312 cites W1881831871 @default.
• W4306952312 cites W2006296021 @default.
• W4306952312 cites W2073700468 @default.
• W4306952312 cites W2087646765 @default.
• W4306952312 cites W2089621382 @default.
• W4306952312 cites W2093274439 @default.
• W4306952312 cites W2115787552 @default.
• W4306952312 cites W2120203545 @default.
• W4306952312 cites W2225937646 @default.
• W4306952312 cites W2336061167 @default.
• W4306952312 cites W2590995222 @default.
• W4306952312 cites W2595086780 @default.
• W4306952312 cites W2791549410 @default.
• W4306952312 cites W2798072661 @default.
• W4306952312 cites W2802842572 @default.
• W4306952312 cites W2948139808 @default.
• W4306952312 cites W2964299611 @default.
• W4306952312 cites W3127713377 @default.
• W4306952312 cites W3163089425 @default.
• W4306952312 cites W3188668922 @default.
• W4306952312 cites W3189636447 @default.
• W4306952312 cites W3193235957 @default.
• W4306952312 cites W4289777162 @default.
• W4306952312 cites W4296148784 @default.
• W4306952312 doi "https://doi.org/10.3390/life12101657" @default.
• W4306952312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36295091" @default.
• W4306952312 hasPublicationYear "2022" @default.
• W4306952312 type Work @default.
• W4306952312 citedByCount "0" @default.
• W4306952312 crossrefType "journal-article" @default.
• W4306952312 hasAuthorship W4306952312A5009702302 @default.
• W4306952312 hasAuthorship W4306952312A5010777746 @default.
• W4306952312 hasAuthorship W4306952312A5020660579 @default.
• W4306952312 hasAuthorship W4306952312A5024526302 @default.
• W4306952312 hasAuthorship W4306952312A5030714095 @default.
• W4306952312 hasAuthorship W4306952312A5031677659 @default.
• W4306952312 hasAuthorship W4306952312A5032117981 @default.
• W4306952312 hasAuthorship W4306952312A5040457683 @default.
• W4306952312 hasAuthorship W4306952312A5055494472 @default.
• W4306952312 hasAuthorship W4306952312A5058333665 @default.
• W4306952312 hasAuthorship W4306952312A5062127717 @default.
• W4306952312 hasAuthorship W4306952312A5068038602 @default.
• W4306952312 hasAuthorship W4306952312A5068127125 @default.
• W4306952312 hasBestOaLocation W43069523121 @default.
• W4306952312 hasConcept C126322002 @default.
• W4306952312 hasConcept C141071460 @default.
• W4306952312 hasConcept C187212893 @default.
• W4306952312 hasConcept C188816634 @default.
• W4306952312 hasConcept C201903717 @default.
• W4306952312 hasConcept C23131810 @default.
• W4306952312 hasConcept C2776301958 @default.
• W4306952312 hasConcept C2778661090 @default.
• W4306952312 hasConcept C2779161974 @default.
• W4306952312 hasConcept C2780011451 @default.
• W4306952312 hasConcept C2780868729 @default.
• W4306952312 hasConcept C2991741193 @default.
• W4306952312 hasConcept C71924100 @default.
• W4306952312 hasConcept C72563966 @default.
• W4306952312 hasConceptScore W4306952312C126322002 @default.
• W4306952312 hasConceptScore W4306952312C141071460 @default.
• W4306952312 hasConceptScore W4306952312C187212893 @default.
• W4306952312 hasConceptScore W4306952312C188816634 @default.
• W4306952312 hasConceptScore W4306952312C201903717 @default.
• W4306952312 hasConceptScore W4306952312C23131810 @default.
• W4306952312 hasConceptScore W4306952312C2776301958 @default.
• W4306952312 hasConceptScore W4306952312C2778661090 @default.
• W4306952312 hasConceptScore W4306952312C2779161974 @default.
• W4306952312 hasConceptScore W4306952312C2780011451 @default.
• W4306952312 hasConceptScore W4306952312C2780868729 @default.
• W4306952312 hasConceptScore W4306952312C2991741193 @default.
• W4306952312 hasConceptScore W4306952312C71924100 @default.
• W4306952312 hasConceptScore W4306952312C72563966 @default.
• W4306952312 hasIssue "10" @default.
• W4306952312 hasLocation W43069523121 @default.
• W4306952312 hasLocation W43069523122 @default.
• W4306952312 hasLocation W43069523123 @default.
• W4306952312 hasOpenAccess W4306952312 @default.
• W4306952312 hasPrimaryLocation W43069523121 @default.
• W4306952312 hasRelatedWork W2173903304 @default.
• W4306952312 hasRelatedWork W2440439573 @default.

• next